| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3357673 | Indian Journal of Rheumatology | 2007 | 8 Pages |
Abstract
Interstitial lung disease (ILD) is now the major cause of mortality in patients with systemic sclerosis (scleroderma) after dramatic reduction in death caused by scleroderma renal crisis, because of the regular use of angiotensin-converting enzyme inhibitors. Treatment of ILD in scleroderma has been somewhat haphazard and treatment protocol often been borrowed from the experience gained from treating ILD of unknown aetiology. The purpose of this review is to outline recent advances and current concepts regarding the management of these ILDs.
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
